Exploring Tumor Treating Fields Therapy
THIS ARTICLE IS SPONSORED BY NOVOCURE®.
This article includes expert insights from Moshe Giladi, PhD; and Narasimha Kumar Karanam, PhD, BCMAS. Giladi, Novocure’s Chief Science Officer, oversees Novocure’s preclinical research organization and manages external research partnerships and Novocure’s biostatistics and data management teams. Karanam is Novocure’s Medical Science Liaison and has researched the mechanisms of action underlying tumor treating fields therapy.
BEST PRACTICES in Managing FGFRi Treatment–Related AEs: Intrahepatic Cholangiocarcinoma
This article is funded by Taiho Oncology, Inc. The publisher is solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this article is not medical advice, and does not replace independent medical judgment.